Incidence of specific infections through 28 days after CAR–T-cell infusion
| Type of infection . | ALL, n = 47 . | CLL, n = 24 . | NHL, n = 62 . | Total, N = 133 . | ||||
|---|---|---|---|---|---|---|---|---|
| Events . | No. of patients (%) . | Events . | No. of patients (%) . | Events . | No. of patients (%) . | Events . | No. of patients (%) . | |
| Any infection | 21 | 14 (29.8) | 8 | 5 (20.8) | 14 | 11 (17.7) | 43 | 30 (22.6) |
| Bacterial infections | 13 | 12 (25.5) | 4 | 4 (16.7) | 7 | 6 (9.7) | 24 | 22 (16.5) |
| Bacteremia* | 8 | 7 (14.9) | 2 | 2 (8.3) | 2 | 1 (1.6) | 12 | 10 (7.5) |
| Bacterial site infections† | 5 | 5 (10.6) | 2 | 2 (8.3) | 5 | 5 (8.1) | 12 | 12 (9.0) |
| Viral infections | 6 | 5 (10.6) | 3 | 2 (8.3) | 4 | 4 (6.5) | 13 | 11 (8.3) |
| Respiratory virus‡ | 6 | 5 (10.6) | 1 | 1 (4.2) | 3 | 3 (4.8) | 10 | 9 (6.8) |
| Other virus§ | 0 | 0 (0.0) | 2 | 1 (4.2) | 1 | 1 (1.6) | 3 | 2 (1.6) |
| Fungal infections|| | 2 | 2 (4.3) | 1 | 1 (4.2) | 3 | 1 (1.6) | 6 | 4 (3.0) |
| Nonmold¶ | 1 | 1 (2.1) | 0 | 0 (0.0) | 3 | 2 (3.2) | 4 | 3 (2.3) |
| Mold# | 1 | 1 (2.1) | 1 | 1 (4.2) | 0 | 0 (0.0) | 2 | 2 (1.5) |
| Type of infection . | ALL, n = 47 . | CLL, n = 24 . | NHL, n = 62 . | Total, N = 133 . | ||||
|---|---|---|---|---|---|---|---|---|
| Events . | No. of patients (%) . | Events . | No. of patients (%) . | Events . | No. of patients (%) . | Events . | No. of patients (%) . | |
| Any infection | 21 | 14 (29.8) | 8 | 5 (20.8) | 14 | 11 (17.7) | 43 | 30 (22.6) |
| Bacterial infections | 13 | 12 (25.5) | 4 | 4 (16.7) | 7 | 6 (9.7) | 24 | 22 (16.5) |
| Bacteremia* | 8 | 7 (14.9) | 2 | 2 (8.3) | 2 | 1 (1.6) | 12 | 10 (7.5) |
| Bacterial site infections† | 5 | 5 (10.6) | 2 | 2 (8.3) | 5 | 5 (8.1) | 12 | 12 (9.0) |
| Viral infections | 6 | 5 (10.6) | 3 | 2 (8.3) | 4 | 4 (6.5) | 13 | 11 (8.3) |
| Respiratory virus‡ | 6 | 5 (10.6) | 1 | 1 (4.2) | 3 | 3 (4.8) | 10 | 9 (6.8) |
| Other virus§ | 0 | 0 (0.0) | 2 | 1 (4.2) | 1 | 1 (1.6) | 3 | 2 (1.6) |
| Fungal infections|| | 2 | 2 (4.3) | 1 | 1 (4.2) | 3 | 1 (1.6) | 6 | 4 (3.0) |
| Nonmold¶ | 1 | 1 (2.1) | 0 | 0 (0.0) | 3 | 2 (3.2) | 4 | 3 (2.3) |
| Mold# | 1 | 1 (2.1) | 1 | 1 (4.2) | 0 | 0 (0.0) | 2 | 2 (1.5) |
“Events” can include multiple entries per patient; the “No. of patients” columns include patients only once per category.
CMV, cytomegalovirus; EBV, Epstein-Barr virus.
Gram-positive, n = 7 (coagulase-negative Staphylococcus aureus, n = 4; streptococcal species, n = 2; Enterococcus faecium, n = 1); gram-negative, n = 4 (Escherichia coli, n = 1; Acinetobacter ursingii, n = 1; Stenotrophomonas maltophilia, n = 1; Capnocytophaga sputigena, n = 1); other, n = 1 (Mycoplasma hominis).
Gastrointestinal tract (C difficile colitis), n = 5; lower respiratory tract, n = 2; skin and soft tissue (perirectal abscesses), n = 3; urinary tract, n = 1; paranasal sinuses, n = 1.
Upper respiratory tract infection, n = 8 (rhinovirus, n = 4; parainfluenza virus 3, n = 1; influenza A, n = 1; metapneumovirus, n = 1; coronavirus, n = 1); lower respiratory tract infection, n = 2 (parainfluenza virus 3, n = 1; parainfluenza virus 4, n = 1).
CMV viremia, n = 1; EBV viremia, n = 1; EBV in cerebrospinal fluid of unclear clinical significance, n = 1.
Lower respiratory tract disease in 3 of 6 events.
Candida glabrata fungemia, n = 2; Candida glabrata pneumonia, n = 1; Candida bracarensis pneumonia, n = 1.
Aspergillus ustus proven pneumonia, n = 1; mold not otherwise specified invasive sinusitis, n = 1.